Results 21 to 30 of about 59,823 (200)

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development

Frontiers in Pharmacology, 2022
Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14–15 months instead of treatment.
Priya Bisht, V. Udaya Kumar, Ruchi Pandey, Ravichandiran Velayutham, Nitesh Kumar   +4 more
doaj   +1 more source

Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma

Oncology Reviews, 2011
Over the past 30 years, there has been no significant improvement in treatment outcomes for patients with advanced stage IV metastatic melanoma, and prognosis remains poor.
Wen-Jen Hwu, Ana E. Ayala, Ingrid M. Hernandez   +2 more
doaj   +1 more source

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide

Frontiers in Oncology, 2020
Glioblastoma, the most common primary central nervous system tumor, is characterized by extensive vascular neoformation and an area of necrosis generated by rapid proliferation.
Monserrat Llaguno-Munive, Monserrat Llaguno-Munive, Sebastián León-Zetina, Inés Vazquez-Lopez, María del Pilar Ramos-Godinez, Luis A. Medina, Luis A. Medina, Patricia Garcia-Lopez   +7 more
doaj   +1 more source

Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway

Frontiers in Cell and Developmental Biology, 2022
Introduction: Glioblastoma (GBM) is invariably resistant to temozolomide (TMZ) chemotherapy. Inhibiting the proteasomal pathway is an emerging strategy to accumulate damaged proteins and inhibit their lysosomal degradation.
Mohummad Aminur Rahman, Mohummad Aminur Rahman, Agnete S. T. Engelsen, Agnete S. T. Engelsen, Shahin Sarowar, Christian Bindesbøll, Even Birkeland, Dorota Goplen, Maria L. Lotsberg, Maria L. Lotsberg, Stian Knappskog, Stian Knappskog, Anne Simonsen, Anne Simonsen, Anne Simonsen, Martha Chekenya   +15 more
doaj   +1 more source

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

ESMO Open, 2020
Background Most glioblastoma tumours exhibit intrinsic phosphatidylinositol 3-kinase (PI3K) pathway activation. Preclinical in vitro and in vivo models suggest that buparlisib (an oral pan-PI3K inhibitor) can have an effect on glioblastoma directly and ...
David Mills, Patrick Yung Wen, Jordi A Rodon, Warren Mason, Joseph T Beck, John DeGroot, Valerie Donnet, Mona El-Hashimy, Mark Rosenthal   +8 more
doaj   +1 more source

Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model

Neoplasia: An International Journal for Oncology Research, 2008
Purpose: The aims of the present work were to investigate the in vitro and in vivo antiangiogenic effects of chronic temozolomide treatment on various glioma models and to demonstrate whether bevacizumab (Avastin) increased the therapeutic benefits ...
Véronique Mathieu, Nancy De Nève, Marie Le Mercier, Janique Dewelle, Jean-François Gaussin, Mischael Dehoux, Robert Kiss, Florence Lefranc   +7 more
doaj   +1 more source

An Unusual Case of Aplastic Anemia Caused by Temozolomide

Case Reports in Medicine, 2010
Radiotherapy and concomitant/adjuvant therapy with temozolomide are a common treatment regimen for children and adults with high-grade glioma. Although temozolomide is generally safe, it can rarely cause life-threatening complications.
Gazi Comez, Alper Sevinc, Ozlem Nuray Sever, Taner Babacan, Ibrahim Sarı, Celalettin Camci   +5 more
doaj   +1 more source

Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report

Journal of Medical Case Reports, 2010
Introduction We report the development of acute lymphoblastic leukemia in a patient in whom temozolomide was used for the treatment of a brain tumor. Unlike that of other alkylating agents, the leukemogenic potential of temozolomide is considered to be ...
Shaikh Asim, Masood Nehal
doaj   +1 more source

Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro.

PLoS ONE, 2019
Glioblastoma is the leading malignant glioma with a poor prognosis. This study aimed to investigate the antitumor effects of natural killer cells in combination with temozolomide as the standard chemotherapeutic agent for glioblastoma.
Yoshitaka Tanaka, Tsutomu Nakazawa, Mitsutoshi Nakamura, Fumihiko Nishimura, Ryosuke Matsuda, Koji Omoto, Yoichi Shida, Toshiharu Murakami, Ichiro Nakagawa, Yasushi Motoyama, Hiromichi Morita, Takahiro Tsujimura, Hiroyuki Nakase   +12 more
doaj   +1 more source

GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to temozolomide

Frontiers in Oncology, 2022
Glioblastoma is a highly lethal grade of astrocytoma with very low median survival. Despite extensive efforts, there is still a lack of alternatives that might improve these prospects. We uncovered that the chemotherapeutic agent temozolomide impinges on
Sweta Parik, Sweta Parik, Sweta Parik, Sweta Parik, Juan Fernández-García, Juan Fernández-García, Francesca Lodi, Francesca Lodi, Karen De Vlaminck, Karen De Vlaminck, Marleen Derweduwe, Steven De Vleeschouwer, Raf Sciot, Wietse Geens, Linqian Weng, Francesca Maria Bosisio, Francesca Maria Bosisio, Gabriele Bergers, Gabriele Bergers, Johnny Duerinck, Frederick De Smet, Diether Lambrechts, Diether Lambrechts, Jo A. Van Ginderachter, Jo A. Van Ginderachter, Sarah-Maria Fendt, Sarah-Maria Fendt   +26 more
doaj   +1 more source